Eli Lilly and Company (NYSE: LLY) and Kelonia Therapeutics, Inc. (“Kelonia”), a clinical-stage biotechnology company pioneering in vivo gene delivery, announce a definitive agreement for Lilly to acquire Kelonia. Kelonia has developed a proprietary in vivo gene placement system (iGPS® ) that uses specially engineered lentiviral-based particles designed to efficiently and selectively enter T-cells inside the body, allowing the patient’s own body to generate chimeric antigen receptor T-cell (CAR-T) therapies that can treat underlying disease. Under the terms of the agreement, Kelonia shareholders will receive up to $7.00 billion in cash, inclusive of an upfront payment of $3.25 billion, and subsequent payments upon achievement of certain clinical, regulatory and commercial milestones.
Read the full article: Lilly to Acquire Kelonia Therapeutics to Advance In Vivo CAR-T Cell Therapies //
Source: https://www.prnewswire.com/news-releases/lilly-to-acquire-kelonia-therapeutics-to-advance-in-vivo-car-t-cell-therapies-302747122.html